Key Releases are ad hoc announcements pursuant to SIX Swiss Exchange Article 53 Listing Rules.
Header
News archive
News Archive Navigation
icon
News Archive Navigation Language
Language Preferences
Showing 121 results
November 2019
-
Key ReleaseNovartis to acquire The Medicines Company for USD 9.7 bn, adding inclisiran, a potentially transformational investigational cholesterol-lowering therapy to address leading global cause of deathOver 50 million secondary prevention patients worldwide with atherosclerotic cardiovascular disease (ASCVD) or familial hypercholesterolemia (FH) on current standard of care do not achieve LDL…
-
Key ReleaseNew Novartis medicine Adakveo® (crizanlizumab) approved by FDA to reduce frequency of pain crises in individuals living with sickle cell diseaseSickle cell pain crises are unpredictable, severe events associated with life-threatening complications1 Adakveo reduced the annual rate of sickle cell pain crises by 45% compared to placebo (1.…
-
Key ReleaseNovartis Cosentyx® shows encouraging results versus Humira®* from first-of-its-kind head-to-head trial in psoriatic arthritisCosentyx narrowly missed statistical significance for superiority in ACR 20, the primary endpoint of the EXCEED trial, while showing numerically higher results versus Humira®*[1] Statistically…
October 2019
-
Key ReleaseNovartis announces AVXS-101 intrathecal study updateFDA placed a partial hold on AVXS-101 intrathecal clinical trials for SMA patients based on findings in a small pre-clinical animal studyAdverse events that might be expected from the pre-clinical…
-
Key ReleaseNovartis delivered another strong quarter with double digit sales growth and core1 margin expansion; 2019 sales and profit guidance raised; Beovu launched in USContinuing operations2 net sales up 13% (cc1, +10% USD) driven by: Cosentyx sales of USD 937 million (+27% cc), with strong demand across indications and regionsEntresto USD 430 million (+61% cc…
-
Key ReleaseNovartis receives FDA approval for Beovu®, offering wet AMD patients vision gains and greater fluid reductions vs afliberceptIn two head-to-head clinical trials, patients on Beovu (brolucizumab) achieved vision gains that were non-inferior to aflibercept at year one with longer treatment intervals in a majority of…
-
Key ReleaseNovartis positive 52-week PREVENT data confirm Cosentyx® efficacy in addressing entire axSpA spectrumPhase III PREVENT study met 52-week primary endpoint of ASAS40, showing a sustained response in patients with non-radiographic axial spondyloarthritis (nr-axSpA)[1] Novartis plans FDA submission…
September 2019
-
Key ReleaseNovartis Kisqali® delivers consistently superior overall survival – MONALEESA-3 trial demonstrates more life for postmenopausal HR+/HER2- advanced breast cancer patientsIn MONALEESA-3, Kisqali plus fulvestrant achieved statistically significant overall survival benefit vs. fulvestrant alone in postmenopausal women (HR=0.724; p=0.00455)[1] Kisqali is the only…
-
Key ReleaseNovartis Cosentyx® positive 16-week PREVENT results advance potential new indication for patients with axial spondyloarthritisPhase III PREVENT study met 16-week primary endpoint of ASAS40 in patients with active non-radiographic axial spondyloarthritis (nr-axSpA). All secondary endpoints were also met [1] Novartis has…
July 2019
-
Key ReleaseNovartis provides update on Phase III PARAGON-HF trial in heart failure patients with preserved ejection fraction (HFpEF)PARAGON study narrowly misses statistical significance on the primary endpoint; overall safety profile confirmed Totality of evidence suggests potential clinically important benefit; results will…
-
Key ReleaseNovartis successfully completes acquisition of Xiidra®, bolstering ophthalmic portfolioBasel, July 1, 2019 - Novartis today announced that it has completed its acquisition of Xiidra® (lifitegrast ophthalmic solution) 5%, the first and only prescription treatment approved to treat both…
Pagination
- ‹ Previous page
- 1
- …
- 4
- 5
- 6
- 7
- 8
- 9
- 10
- 11
- › Next page